Enter assignee name

% Expired Patents = 55.6

EPO Patents = 3

Forward Citations = 64

Loading Chart...

4 inventors (with patents filed for the assignee):

Jeffrey M Greve (9 out of 40 patents)

Niranjana Aditi Nagarajan (2 out of 4 patents)

Jungmin Kim (2 out of 2 patents)

4. John Cho (2 out of 2 patents)

9 patents: Sort by Forward Citations

1. 11535657 - Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases (2022-12-27),

2. 11077172 - IL-2 variants for the treatment of psoriasis (2021-08-03),

3. 11059877 - Multivalent regulatory T cell modulators (2021-07-13),

4. 10875901 - Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases (2020-12-29),

5. 10774126 - Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases (2020-09-15),

6. 10766938 - Nucleic acid encoding human IL-2 variant (2020-09-08),

7. 10472405 - Multivalent regulatory T cell modulators (2019-11-12),

8. 10294287 - Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases (2019-05-21),

9. 10035836 - Modified IL-2 variants that selectively activate regulatory T cells (2018-07-31),

Delinia, Inc. is a biotechnology company focused on developing novel treatments for autoimmune diseases. Our proprietary technology platform harnesses the power of the immune system to create personalized therapies for patients. With a team of experienced scientists and experts, Delinia is at the forefront of advancing precision medicine in the field of autoimmune diseases.

This text is generated by artificial intelligence and may not be accurate.